Selective cytokine inhibitory drugs for treating disorders of the central nervous system

A cytokine-selective technology that can be used in neurological diseases, non-central analgesics, digestive system, etc. to solve problems such as increased synthesis and release of norepinephrine, long-term memory deficits, and limited clinical use

Inactive Publication Date: 2010-05-12
CELGENE CORP
View PDF39 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Zhu et al., CNS Drug Reviews, Vol.7, No.4, 387-398, 2001. It is reported that PDE4 is mainly used for the hydrolysis of cyclic nucleotides cAMP and cGMP, especially in nerve and immune cells. Same as above. Ripram causes an increase in intracellular cAMP and increases the synthesis and release of norepinephrine, which enhances central noradrenergic transmission. Ibid. Rolipram attenuates endogenous depression and Inflammation. Ibid. However, there are some discrepancies between the in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selective cytokine inhibitory drugs for treating disorders of the central nervous system
  • Selective cytokine inhibitory drugs for treating disorders of the central nervous system
  • Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0034] The first embodiment of the present invention includes a method of treating or preventing central nervous system diseases, the method comprising administering to a patient in need of such treatment or prevention a therapeutically or preventively effective amount of a selective cytokine inhibitory drug, or a pharmaceutically acceptable Accepted salts, solvates, hydrates, stereoisomers, clathrates or prodrugs. Central nervous system diseases include but are not limited to Parkinson's disease; bradykinesia; muscle rigidity; Parkinson's tremor; Parkinson's gait; motor freezing; depression; lack of long-term memory; Rubinstein-Taybi syndrome (RTS); dementia; sleep Disorders; postural instability; hypokinesia disorder; inflammation; synuclein disorder; multiple system atrophy (artrophies); striatal substantia nigra degeneration; olive pontine cerebellar atrophy; Shy-Drager syndrome; movement with characteristics of Parkinson's disease Neuron disease; Lewy body dementia; Tau (T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Description

1. Field of invention [0001] The present invention relates in part to methods of treating, preventing and / or managing disorders of the central nervous system including, but not limited to, Parkinson's disease, Alzheimer's disease, mild cognitive impairment, Huntington's disease, muscular atrophy Lateral sclerosis, depression and long-term memory loss and related diseases, the method comprising administering selective cytokine inhibitory drugs or pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates thereof or prodrugs. 2. Background of the invention [0002] CNS disorders affect a wide range of populations to varying degrees. In general, a major feature of such disorders includes marked cognitive or memory impairment, which represents a marked regression of previous levels of functioning. Dementia, for example, characterized by several cognitive impairments including marked memory deficits and which may be present alone or as a predominant featur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4035A61K31/553A61K31/554A61K45/06
CPCA61K45/06A61K31/554A61K31/553A61P1/08A61P25/00A61P25/08A61P25/14A61P25/16A61P25/20A61P25/24A61P25/28A61P29/00A61P43/00A61K31/4035
Inventor P·H·夏菲尔
Owner CELGENE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap